{"id":124845,"date":"2026-09-03T04:22:27","date_gmt":"2026-09-03T04:22:27","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/124845\/"},"modified":"2026-09-03T04:22:27","modified_gmt":"2026-09-03T04:22:27","slug":"fda-approves-new-alzheimers-blood-test-from-roche-eli-lilly-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/124845\/","title":{"rendered":"FDA approves new Alzheimer\u2019s blood test from Roche, Eli Lilly"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">Alzheimer&#8217;s is a disease that touches millions \u2014 both those with a diagnosis and their loved ones.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">In <a data-ylk=\"slk:Indiana;elm:context_link;itc:0;sec:content-canvas;\" data-yga=\"{&quot;yLinkElement&quot;:&quot;link&quot;,&quot;yLinkElementType&quot;:&quot;article_link&quot;}\" href=\"http:\/\/wthr.com\/indiana\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">Indiana <\/a>alone, more than 121,000 people aged 65 and older have Alzheimer&#8217;s. It likely affects many more, too. The World Alzheimer Report suggests <a data-ylk=\"slk:75%25 of all dementia cases;elm:context_link;itc:0;sec:content-canvas;\" data-yga=\"{&quot;yLinkElement&quot;:&quot;link&quot;,&quot;yLinkElementType&quot;:&quot;article_link&quot;}\" href=\"https:\/\/www.alzint.org\/news-events\/news\/over-41-million-cases-of-dementia-go-undiagnosed-across-the-globe-world-alzheimer-report-reveals\/\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">75% of all dementia cases<\/a> aren&#8217;t diagnosed.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The FDA just granted Indianapolis-based Roche Diagnostics and partner Eli Lilly approval for its new blood test. The test will help identify the signs of Alzheimer&#8217;s in people aged 55 and older who are already showing signs of cognitive decline.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The test, Elecsys pTau217, is a biomarker blood test. Doctors are looking for amyloid, a protein linked to the disease, which can signify if a patient is likely to have Alzheimer&#8217;s or not. It can provide a positive, intermediate or negative result.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">&#8220;They were looking at this biomarker called pTau217, and it has been validated and associated with Alzheimer&#8217;s disease pathology, and it&#8217;s a really good market for identifying those patients who have the disease,&#8221; said Chris Stamatkin, a medical science liaison with Roche U.S. Medical Affairs.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">While not a standalone diagnostic test, the idea is that it&#8217;s simpler and more accessible to people than the typical PET scan or cerebrospinal fluid testing used to detect amyloid.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">&#8220;Both are relatively invasive and cost-prohibitive, or lack a lot of availability for our patients around Indiana,&#8221; Stamatkin said.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">For decades, an Alzheimer&#8217;s diagnosis came with few options, but in recent years, that&#8217;s starting to change, with new therapies slowing its progression. But timing is critical \u2014 those therapies don&#8217;t reverse Alzheimer&#8217;s and work best earlier on in the disease&#8217;s progression. It&#8217;s why getting a diagnosis early on is so important.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">&#8220;I see this as being one more tool in the toolbox that allows us to really get a diagnosis earlier on for these patients,&#8221; Stamatkin said. &#8220;These patients who are showing up, really showing those earliest symptoms to allow for them to get from that stage as quickly as possible to those new therapeutics is key, and this is really kind of bridging that gap.&#8221;<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">This blood test also already has European approval.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">It can be run on more than 4,500 Roche laboratory analyzers in the U.S. Labcorp and Quest Diagnostics announced Monday they plan to offer the test through their laboratory networks, as well.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Insurance provider Anthem also covers blood-based biomarker testing if it&#8217;s FDA approved or measures pTau217. Its policy requires the individual be older than 50 and must meet any of the following criteria, too:<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">To triage the need for cerebrospinal fluid testing or PET imaging;<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">As an alternative when CSF testing is not feasible;<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">To assess for neuropsychiatric referral or evaluation.<\/p>\n","protected":false},"excerpt":{"rendered":"Alzheimer&#8217;s is a disease that touches millions \u2014 both those with a diagnosis and their loved ones. In&hellip;\n","protected":false},"author":2,"featured_media":124846,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[4337,134,2057,61015,61016],"class_list":["post-124845","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-fda","tag-roche","tag-roche-diagnostics","tag-roche-u-s-medical-affairs","tag-stamatkin"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117205201384986352","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=124845"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124845\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/124846"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=124845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=124845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=124845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}